Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from December 18, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on March 18, 2026.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$100.28 Published $108.30 Target $114.50 Window close $125.14 Peak
$98.00 – $101.00Entry zone — fair-value band
$100.28Published — price the day we called it
$108.30Target — the price the thesis aimed for
$125.14Peak — highest point inside the window, not a realized return
$114.50Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 18 days.

Peak price
$125.14
peak on February 25, 2026 — not a realized return
Peak gain
+24.8%
peak, from the publication price
Window close
$114.50
end-of-window price, context only
Days to target
18
Window
December 18, 2025 – March 18, 2026

The thesis — published December 18, 2025

Predicted growth
+8%
over the measurement window
Target price
$108.30
the price the thesis aimed for
Entry zone
$98.00 – $101.00
the fair-value band we waited for
Price at publication
$100.28
published December 18, 2025
Confidence
62%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck is a defensive pick because positive European news for WINREVAIR makes investors more confident in its drug pipeline and lowers short-term downside risk into 2026. Price readings show it's been pushed lower recently, but the overall trend is still weak, so expect a short-term bounce rather than a clear recovery. Keep positions small and wait for the price to stabilize before adding.

Primary drivers

  • Positive WINREVAIR news improves investor confidence in the pipeline
  • Recent oversold readings can cause a short-term rebound
  • Healthcare stocks often attract money when tech is shaky
  • Staggered buys limit losses while trend remains unclear

How it played out

MRK: target reached in 18 days

Lyra published MRK at $100.28 on December 18, 2025, with an 8% expected gain and a $108.30 target. The thesis pointed to positive WINREVAIR news, oversold price readings, defensive healthcare demand when tech was shaky, and staggered buys while the trend stayed unclear.

Inside the window, MRK reached the target in 18 days. It later peaked at $125.14 on February 25, 2026, for a 24.8% gain. The signal ended at $114.50 on March 18, 2026. The thesis played out. The bounce was not only reached, it went well past the target.

What happened during the window

On February 3, 2026, Merck reported fourth-quarter 2025 revenue of $16.4 billion and adjusted earnings of $2.04 per share. The same day, it issued 2026 revenue guidance of $65.5 billion to $67.0 billion and adjusted earnings guidance of $5.00 to $5.15 per share.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals